CELESTONE CHRONODOSE

This brand name is authorized in Australia, Estonia, Spain, Israel, New Zealand, Turkey

Active ingredients

The drug CELESTONE CHRONODOSE contains a combination of these active pharmaceutical ingredients (APIs):

1 Betamethasone sodium phosphate UNII 7BK02SCL3W - BETAMETHASONE SODIUM PHOSPHATE

Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Read about Betamethasone

2 Betamethasone acetate UNII TI05AO53L7 - BETAMETHASONE ACETATE

Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Read about Betamethasone

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H02AB01	Betamethasone	H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN → H02AB Glucocorticoids
Discover more medicines within H02AB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2694T, 5034Y
Country: EE	Ravimiamet	Identifier(s): 1110216, 1421367, 1516621, 1783199
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 40628
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 1233
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 5625
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8683280337039